Science Links Japan | Medicine & Drug Journal

List of Jounal Titles

A to Z index of Journal Title. Choose a letter.

A/ B/ C/ D/ E/ F/ G/ H/ I/ J/ K/ L/ M/ N/ O/ P/ Q/ R/ S/ T/ U/ V/ W/ X/ Y/ Z/ 0/ 1/ 2/ 3/ 4/ 5/ 6/ 7/ 8/ 9

Medicine & Drug Journal

New pharmacotherapy DDS opens up. Advance of drug discovery science and technology and future DDS development.
New pharmacotherapy DDS opens up. 1. Control of drug digestive absorption. Absorption improvement of peptide drug.
New pharmacotherapy DDS opens up. 2. DDS using drug transporter.
New pharmacotherapy DDS opens up. 3. New technology and new material utilized for the development of oral sustained release preparation.
New pharmacotherapy DDS opens up. 4. Pharmacokinetics and drug targeting of nano DDS.
New pharmacotherapy DDS opens up. 5. Functional lipid microemulsion and DDS.
New pharmacotherapy DDS opens up. 6. Targeting and metastasis control of active oxygen quenching enzyme.
New pharmacotherapy DDS opens up. 7. Active oxygen and free radical and DDS.
New pharmacotherapy DDS opens up. 8. Diagnosis and treatment of cancer and DDS. Diagnosis of lymph node metastasis of gastric cancer by Combidex of MRI contrast media.
New pharmacotherapy DDS opens up. 9. Photodynamic therapy and DDS.
New pharmacotherapy DDS opens up. 10. Promotion of the gene delivery efficiency by intracellular dynamics control.
New drug prospect in 2004. First part. How to utilize clinical trial information in the clinical field. General remarks on how to utilize clinical trial information in the clinical field.
New drug prospect in 2004. First part. How to utilize clinical trial information in the clinical field. From the viewpoint of the medical specialist of diabetes mellitus.
New drug prospect in 2004. First part. How to utilize clinical trial information in the clinical field. From the viewpoint of the medical specialist of cancer.
New drug prospect in 2004. First part. How to utilize clinical trial information in the clinical field. As a pharmacist based on the experience of drug review.
New drug prospect in 2004. First part. How to utilize clinical trial information in the clinical field. Recent trend of judging for new drugs approval.
New drug prospect in 2004. Second part. Notable new drug. Drug for hyperphosphatemia. Sevelamer hydrochloride. Sevelamer hydrochloride.
New drug prospect in 2004. Second part. Notable new drug. HMG-CoA reductase inhibitor. Pitavastatin.
New drug prospect in 2004. Second part. Notable new drug. Antiantiparkinson drug. Pramipexole.
New drug prospect in 2004. Second part. Notable new drug. Dihydropyridine derivative calcium antagonist. Azelnidipine. Unique character as the new prolonged action calcium antagonist.
New drug prospect in 2004. Second part. Notable new drug. Anticancer drug. Capecitabine.
New drug prospect in 2004. Second part. Notable new drug. Antihuman TNF.ALPHA. monoclonal antibody. Infliximab.
New drug prospect in 2004. Second part. Notable new drug. Prolonged action drug for cancer pain. Oxycodone sustained release tablet.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Square of the new drug. Antimicrobial agent for injection.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Oral antibacterial agent.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antiviral agent.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. New anti-HIV drug of the once a day ingestion for ingestion rate improvement.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Vaccine.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Disinfectant.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Therapeutic drug for digestive cancer.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Therapeutic drug for lung cancer.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Therapeutic drug for mammary cancer.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Therapeutic drug for uterine tumor.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Drug for leukemia and drug for malignant lymphoma.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antitumor drug. Drug for treatment of bladder cancer and prostatic cancer.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Immunosuppressant.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Analgesic for cancer pain.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Cancer therapy adjuvant.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Adrenocortical steroid (external use).
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. COX-2 inhibitor.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antirheumatic drug.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antiallergic agent.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antidiabetic drug. New insulin analog preparation.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of diabetic complication.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Hormone preparation.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of osteoporosis.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Fluid therapy and dialysis fluid.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. New drug for anticoagulation and antiplatelet therapy.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Hypolipidemic drug.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antiarrhythmic drug..
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of cardiac insufficiency.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of hypertension.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of COPD (chronic obstructive lung disease). Centering on tiotropium bromide.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Gastrointestinal drug.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. H. Pylori bacteria elimination and combination therapy with three agents.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antianxiety agent. Selective serotonin reuptake inhibitor (SSRI).
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for hemicrania.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Anticonvulsant centering on lamotrigine.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antipsychotic drug.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of manic-depressive psychosis.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of cerebrovascular disorder including drug for Alzheimer disease.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Antiparkinson drug.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of atopic dermatitis including immunomodulator.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. External use antibacterial agent.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. External use drug except for the antibacterial agent.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Drug for treatment of urination disorder and collection of urine failure.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Contrast media.
New drug prospect in 2004. Third part. Positioning of latest new drug in the treatment. Diagnostic agent, diagnostic aid agent.
1
Contact dermatitis due to the chemical substance. (52) Detailed explanation. 45. Dermatopathy due to ricinoleic acid.
EBM and role of statistics. Indispensable knowledge for reading medical information.
Parkinsonism as the drug side effect. 1. Drug-induced Parkinsonism and Parkinson disease. General remarks.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 1). Phenothiazine antipsychotic drug.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. Butyrophenone antipsychotic drug.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 3). Benzamide antipsychotic drug including the drugs which belong to gastrointestinal function adjustment drug and antiemetics, etc.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 4). Atypical antipsychotic drug as the other antipsychotic drug.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 5). Calcium antagonist.
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 6) Central and peripheral sympatholytic antihypertensive agent (reserpine, methyldopa).
Parkinsonism as the drug side effect. 2. Parkinsonism as the side effects of various drugs. Origins, features and measures. 7) Points of patient compliance instruction and prescription support.
Parkinsonism as the drug side effect. 3. MPTP, 6-hydroxydopamine and rotenone as the drug used in the experimental Parkinsonism.
Risk management- in-hospital activity by the pharmacist- (22). Construction of child dose check system for the medical treatment error prevention.
Prescription support by the pharmacist. 1. Side effect prevention by gene diagnosis.
Interaction between food and drug. 52. I. Adverse effects generated in the encounter of drug and food and favorite food. 1. Food and favorite food make drug into poison. j). Drug and salt.
Improvement of patient QOL and involvement of the pharmacist. PARTI. Hospital preparation (29). Examination of the oral formulation of acetaminophen for the purpose of the bitterness control.
Pharmacological basic knowledge required in the clinic field. 27. Database preparation provided for the disaster medical treatment.
Follow-up report. Practical recording of pharmacological management (1). Essential sheet and follow-up sheet. Urology region - I.(edition in the perioperative period).
2
Dermatopathy by the chemical substance. (53)Detailed explanation. 46. Contact dermatitis by palladium.
Present states and pharmacotherapy of tuberculosis. 2. Bacteriology of acid-fast bacteria. Recent topics about taxonomy.
Present states and pharmacotherapy of tuberculosis. 3. Immunology of tuberculosis.
Present states and pharmacotherapy of tuberculosis. 4. Tuberculin reaction and future tuberculosis infection diagnosis.
Present states and pharmacotherapy of tuberculosis. 5. Molecular epidemiology.
Present states and pharmacotherapy of tuberculosis. 6. Chemotherapy for tuberculosis.
Present states and pharmacotherapy of tuberculosis. 7. Directory observed treatment, short course (DOTS).
Present states and pharmacotherapy of tuberculosis. 8. Senile tuberculosis.
Present states and pharmacotherapy of tuberculosis. 9. Mass outbreak including the significance of BCG vaccination.
Present states and pharmacotherapy of tuberculosis. 10. Measures for the compromised host person including preventive internal administration.
Present states and pharmacotherapy of tuberculosis. 11. Problem in the developing country, especially the problem of the AIDS complicated tuberculosis.
Risk management. Nosocomial activity by the pharmacist. (23). Effective operation of chemotherapy protocol check.
Prescription support by the pharmacist. 2. Trial for proper use of the drug considering the patient genetic information.
Interaction between food and drug. 53. II. Failure of the treatment which is caused in the encounter of drug and food and favorite food. 2. The pharmacological effect lowers due to the decreased small intestine absorption of the drug. g). Drug and dietary fiber.
QOL improvement in the patient and involvement of pharmacist. PART II. Patient compliance instruction and ward activity (39). Dosage form of the internal medicine and the problem of swallowing with the aim of the clinical application.
Pharmacological basic knowledge required in the clinic field. 28. Outlines and usefulness of lipid and fat emulsion for the intravenous infusion.
Follow-up report. Practical record of pharmacological management. Essential sheet and follow-up sheet. Urology region - II (renal cell carcinoma text).
Formidable infertility. Beginning of ascites filtration concentration reflux method.
3
Dermatopathy due to the chemical substance. (54)Detailed explanation. 47. Contact dermatitis by Chinese chrysanthemum.
Sex difference and EBM of pharmacotherapy.
Sexually transmitted disease in our country and pharmacotherapy. 1. Present states of the sexually transmitted disease in our country.
Sexually transmitted disease in our country and pharmacotherapy. 2. Pharmacotherapy for HIV infection/AIDS.
Sexually transmitted disease in our country and pharmacotherapy. 3. Pharmacotherapy for genital Chlamydia infection (man).
Sexually transmitted disease in our country and pharmacotherapy. 4. Pharmacotherapy for genital Chlamydia infection (woman).
Sexually transmitted disease in our country and pharmacotherapy. 5. Pharmacotherapy for gonococcal infection.
Sexually transmitted disease in our country and pharmacotherapy. 6. Pharmacotherapy for genital herpes infectious disease.
Sexually transmitted disease in our country and pharmacotherapy. 7. Present states and prospect of the HPV vaccine development.
Effect of fexofenadine hydrochloride on pruritus cutaneus of the dialysis patient.
Actual condition survey of the use of inhaled corticosteroid in the asthmatic patient.
Comparison of dissolution behavior of the theophylline sustained release dry syrup preparation.
Risk management. Activity of the pharmacist in the hospital. (24). Introduction of RCA to the medical treatment safety measure and activities by the pharmaceutical department. Utilization of the incident report.
Prescription support by the pharmacist. (3). Prescription support method that the pharmacist can do. Ward activity and utilization of the database.
Interaction between drug and food. 54. II. Failure of the treatment caused in the encounter of drug and food and favorite food. 3. Food attenuates action of drug in the action site. a). Drug and high protein diet (amino acid).
QOL improvement of the patient and involvement of the pharmacist. PART I. Hospital formulation. (30). Stability and usefulness of cyclosporin eye drop.
QOL improvement of the patient and involvement of the pharmacist. PART II. Patient compliance instruction and ward activity. (40). The opening of the ambulatory service of the drug for the diabetic.
Pharmacological basic knowledge required in the clinic field. (29). Patient who often skips breakfast. Whether the drug should be taken.
Practical record of the pharmacological control in series. (3). Essential sheet and follow-up sheet. Urology region - III. Bladder malignant tumor edition.
Xerosis and Sjoegren. 12. Xerostomia. Interaction between cevimeline hydrochloride and antidepressive drug based on pharmacodynamics.
4
Dermatopathy by chemical substance. (55) Detailed explanation. 48. Contact dermatitis due to the rabbit scarf.
Ideal way of proper use of the antibacterial agent based on PK/PD.
Evolution! Deepening! Renewal!? Clinical pass. 1. Reforming pharmacist and hospital. 1) Drug management guidance work. Preparation of clinical pass for patient compliance instruction by variance analysis and the use effect.
Evolution! Deepening! Renewal!? Clinical pass. 1. Reforming pharmacist and hospital. 2) International organization for standardization (ISO). ISO approval acquisition by pharmacy.
Evolution! Deepening! Renewal!? Clinical pass. 1. Reforming pharmacist and hospital. 3) Medical treatment cooperation. Sharing of patient information between hospitals.
Evolution! Deepening! Renewal!? Clinical pass. 1. Reforming pharmacist and hospital. 4) Drug economy. Review of the preventive administration of the antibacterial agent by the clinical pass.
Evolution! Deepening! Renewal!? Clinical pass. 1. Reforming pharmacist and hospital. 5) Team medical treatment. Participation in the team medical treatment promotion with critical pathway by pharmacy.
Evolution! Deepening! Renewal!? Clinical pass. 2. Clinical pass as the science. 1) Quality improvement of the medical care. Clinical pass as the standard.
Evolution! Deepening! Renewal!? Clinical pass. 2. Clinical pass as the science. 2) IT: Electronic medical record.
Evolution! Deepening! Renewal!? Clinical pass. 2. Clinical pass as the science. 3) Medical environment and hospital organization. Whether the hospital changes by clinical pass.
Evolution! Deepening! Renewal!? Clinical pass. 2. Clinical pass as the science. 4) Efficiency improvement in the pass record shared in the medical record team.
Evolution! Deepening! Renewal!? Clinical pass. 2. Clinical pass as the science. 5) Clinical pass from the viewpoint of the hospital management. Business management, especially from the viewpoint of the receipts and payments management.
Clinical significance of the immunosuppressant sensitivity test by the MTT assay method demonstrated from the experience in kidney transplantation.
Risk management. Activity by the pharmacist inside the House. (25) Examination of the medication error prevention system using FMEA (failure mode and effects analysis).
Prescription support by the pharmacist. (4). The contribution to the avoidance of the drug interaction by the pharmacist.
Interaction between drug and food. 55 II. Failure of the treatment which occurs in the encounter of drug and food and favorite food. 4. Drug invalidates the action of vitamin. a) Drug and food, favorite food, health food and nutriment containing vitamin K.
QOL improvement of the patient and involvement of the pharmacist. PART II. Patient compliance instruction and ward activity (41). Ward pharmacist who is well thought of by the patient.
Pharmacological basic knowledge required in the clinical field (30). Nutritional treatment of the liver cirrhosis patient. Medication method of oral nutrient for liver failure.
Practical record of pharmacological management of continuance (4). Essential sheet and follow-up sheet. Urology region. IV. Chapter on renal pelvis, ureter malignant tumor, testiculus tumor.
5
Dermatopathy due to chemical substance.(56)Detailed explanation. 49. Allergic contact dermatitis due to nickel.
Procalcitonin test and antibacterial agent use restraint. Whether to be administered or not to be administered.
Drug discovery using the molecular mechanism of the drug transporter group.
The 6 years system in pharmacopedia and future prospect. Problem of the 6 years system in pharmacopedia.
PET (positron emission tomography). Diagnostic imaging identified so far. In place of the introduction.
PET (positron emission tomography). Diagnostic imaging identified so far. Basics of PET.
PET (positron emission tomography). Diagnostic imaging identified so far. PET and cerebral blood flow.
PET (positron emission tomography). Diagnostic imaging identified so far. 3. PET and receptor. Receptor functional analysis of brain and heart muscle.
PET (positron emission tomography). Diagnostic imaging identified so far. 4. Application of PET to the circulatory disease.
PET (positron emission tomography). Diagnostic imaging identified so far. 5. Tumor screening by FDG-PET.
PET (positron emission tomography). Diagnostic imaging identified so far. 6. Oncotherapy evaluation by PET.
PET (positron emission tomography). Diagnostic imaging identified so far. 7. Utilization of PET in the drug development.
Examination of the negative conversion rate after treatment of Chlamydia trachomatis-induced cervicitis and pharyngitis.
Compounding change of the prostaglandin E1 preparation (lipo PGE1) for intravenous infusion on sale.
Risk management. Activity by the hospital pharmacist. (26). Construction of prescription ordering system for preventing the inappropriate prescription.
Prescription support by the pharmacist. 5. Prescription support by the pharmacist in postoperative ambulatory treatment in liver transplantation from living donor between adults. Prescription drug in the postoperative internal medicine region.
Interaction between drug and food. 56. II. Failure of the treatment caused by the encounter of drug and food and favorite food. 4. Drugs invalidate the action of vitamin. b) Drug and food, favorite food, health food and nutriment containing vitamin B12.
QOL improvement of the patient and involvement of the pharmacist. PART II. Patient compliance instruction and ward activity (42). Role of the fulltime pharmacist in ambulatory cancer chemotherapy. For patient compliance instruction to the patient.
Pharmacological basic knowledge required in the clinical field. 31. The role of pharmacist at NST (Nutrition Support Team). Specialty in team medical treatment.
Sequel to practice record of pharmacological management (5). Essential sheet and follow-up sheet. Urology region V. Volume of the prostatic disease.
Xerosis and Sjoegren. 13. Usage of cevimerine hydrochloride (Saligren) for xerostomia associated with Sjoegren syndrome. Especially the oral cavity rinse method.
6
Dermatopathy due to chemical substance.(57). Detailed explanation. 50. Allergic contact dermatitis due to p-tert-butyl phenol formaldehyde resin.
View on phase IV study (post-marketing clinical trial)!
The problem of the doctor leading clinical trial.
View on the pharmacist education in U.S.A. and the 6-year system education. 1. Overseas study in Florida University.
View on the pharmacist education in U.S.A. and the 6-year system education. 2. From the viewpoint at school in the 3rd grade of Pharm. D. in Florida University.
View on the pharmacist education in U.S.A. and the 6-year system education. 3. As a student of Tennessee University.
View on the pharmacist education in U.S.A. and the 6-year system education. 4. Upon receiving clinical practice for 6 months in Mississippi University.
View on the pharmacist education in U.S.A. and the 6-year system education. 5. Overseas study in Arizona University.
View on the pharmacist education in U.S.A. and the 6-year system education. 6. Pharmacist education in U.S.A.
View on the pharmacist education in U.S.A. and the 6-year system education. 7. Examination on pharmacist education in U.S.A. and 6-year education system in Japan (1).
View on the pharmacist education in U.S.A. and the 6-year system education. 8. Examination on pharmacist education in U.S.A. and 6-year education system in Japan (2).
Relationship between hepatic disorders caused by the acetaminophen dosing and gene polymorphism of CYP2E1 and GSTM1 of metabolizing enzyme.
Prescription support by the pharmacist (6). Fluid therapy related information necessary for the prescription inspection of the injection.
Interaction between drug and food. (57). II. Failure of the treatment caused by the encounter of drug, food and favorite food. 4. Drug invalidates the action of vitamin. c). Drug interaction with food, favorite food, health food and nutriment containing vitamin D.
QOL improvement of patient QOL and involvement of pharmacist. PART I. Hospital preparation. (31). Pharmaceutical examination for the purpose of the rectal absorption improvement for the rifampicin suppository.
QOL improvement of patient QOL and involvement of pharmacist. PART II. Patient compliance instruction and ward activity. (43). Standard care plan introduction to multiple myeloma of the elderly person and the result.
Pharmacological basic knowledge required in the clinical field (32). Activities toward proper use of preventive antibacterial agent for postoperative infection. With the aim of the improvement in the quality of drug management guidance work.
Sequel. Practical record of pharmacological management (6). Essential sheet and follow-up sheet. Urology region - VI. Kidney transplantation edition.
Xerosis and Sjoegren. (14). History of Sjoegren syndrome and establishment of disease concept.
Formidable infertility. (12). Infertility after SLE treatment.
7
Dermatopathy due to chemical substance. (58)Detailed explanation. 51. Allergic contact dermatitis due to rosin (colophony) and the derivative.
Future of OTC of statin. Simvastatin in U. K. as the first OTC in the world. What a Paxil accusation case in U.S.A. proposes. EBM and publication bias.
Merits and demerits of the anticancer drug indication extension.
Global development for drug discovery science. Sponsorship of Pharmaceutical Sciences World Congress, PSWC2004.
View on the drug outside the indication. 1. Use of the drug outside the indication. What has been studied and changed since 1995 years.
View on the drug outside the indication. 2. From the viewpoint of clinical pharmacology.
View on the drug outside the indication. 3. From the viewpoint of the hospital pharmacy.
View on the drug outside the indication. 4. From the viewpoint of the doctor. 1). General problems on medical specialty.
View on the drug outside the indication. 4. From the viewpoint of the doctor. 2) Centering on cancer therapeutic drug.
View on the drug outside the indication. 4. From the viewpoint of the doctor. 3) Centering on the pediatric region.
View on the drug outside the indication. 5. From the viewpoint of the pharmaceutical company.
View on the drug outside the indication. 6. Operation and utilization situation of database of the drug for use outside the indication.
View on the drug outside the indication. 7. From the viewpoint of administration. Problems on the use outside the indication.
Action of cyclosporin. Clarified diversity. 1. General remarks. Action of cyclosporin on cyclophilin.
Action of cyclosporin. Clarified diversity. 2. HCV antiproliferative activity of cyclosporin.
Action of cyclosporin. Clarified diversity. 3. Action of cyclosporin on pancreatic .BETA. cell.
Action of cyclosporin. Clarified diversity. 4. Action of cyclosporin on keratinocyte.
Action of cyclosporin. Clarified diversity. 5. Action of cyclosporin on mast cell.
Action of cyclosporin. Clarified diversity. 6. Action of cyclosporin on mitochondrial membrane permeability.
Action of cyclosporin. Clarified diversity. 7. Action of cyclosporin on P - glycoprotein. Conquest of drug resistance.
Action of cyclosporin. Clarified diversity. 8. Action of cyclosporin on new chronic allergic inflammatory reaction induced in gene modified model animal.
Action of cyclosporin. Clarified diversity. 9. Action of cyclosporin on MMP.
Action of cyclosporin. Clarified diversity. 10. Cyclosporin and control of p38MAPK and JNK.
Drug for treatment of migraine. Transition of triptan drug and the dosage form.
Drug interaction test of dobutamine hydrochloride injection (Dobutrex).
Clinical pass and pharmacist (17). Know-how of planning and practice. Activity to patient compliance instruction for which the medicine counseling room is utilized for clinical pass of the short-term hospitalized patient.
Prescription support by the pharmacist (7). Avoidance measures for overturn and fall accident of the elderly person. Prescription design support for sleep inducing agent.
Interaction between drug and food. 58. II. Failure of the treatment which occurs in the encounter of drug, food and favorite food. 4. Drug invalidates the action of vitamin. d). Drug, and favorite food, health food and nutriment including coenzyme Q10.
QOL improvement in the patient and participation of the pharmacist. PART II. Patient compliance instruction and ward activity (44). Promotion of proper use of pharmaceutical products according to the hierarchized product documents information (e product documents).
Pharmacological basic knowledge required in the clinical field. (33). Blood pressure lowering due to diclofenac sodium suppository.
Sequel. Practical record of pharmacological management (7). Essential sheet and follow-up sheet. Circulatory internal medicine region - I. Ischemic heart disease, part 1.
Xerosis and Sjoegren (15). Serum finding as a beginning of the detection of Sjoegren syndrome.
8
Dermatopathy due to chemical substance. (59). Detailed explanation. 52. Allergic contact dermatitis due to marking pen.
Symptom of generalized anxiety disorders and actual conditions.
Six-year pharmacopedia system and future prospect. With the aim of the construction of the pharmacopedia boasting to the world.
Future OTC drug. 1. General remarks.
Future OTC drug. 2. The job which the pharmacist should fulfil in OTC drug sales.
Future OTC drug. 3. How should OTC drug information be transmitted to the habitant?
Future OTC drug. 4. Legal regulation on OTC drug.
Future OTC drug. 5. World circumstance of OTC drug.
Future OTC drug. 6. Adverse drug reactions of OTC drug.
Future OTC drug. 7. From the manufacturing to the sale of OTC drug.
Future OTC drug. 8. Proper use of OTC drug.
DRG-PPS and antimicrobial therapy.
Quick determination of serum total bromine by energy dispersive X-ray fluorescence analysis.
Consideration on the choice of the inhaled steroid medicine.
Risk management. In-hospital activity by the pharmacist (27). Establishment of the mixed injection center which brings the risk management into view.
Clinical pass and pharmacist (18). Know-how of plan and practice. Involvement of the pharmacist in the clinical pass by using the prescription. Cardiovascular surgery and division of cardiovascular disease.
Prescription support by the pharmacist (8). Prescription support by the pharmacist in the intensive care region. Participation in fluid therapy prescription design during the operation of blood purification therapy.
Interaction between drug and food. 59. II. Failure of treatment which occurs in the encounter of drug, food and favorite food. 4. Drug invalidates the action of vitamin. e) Drug and food, favorite food, health food and nutriment containing folic acid.
Patient QOL improvement and involvement of pharmacist. PART I. Hospital formulation. (32). Preparation of new indometacin spray for the purpose of the pain management of stomatitis and pharmaceutical examination.
Pharmacological basic knowledge required in the clinical field (34). Pharmacology of Biolactis. Infection preventive effects.
The sequel. Practical record of pharmacological management (8). Essential sheet and follow-up sheet. Cardiovascular internal medicine domain - II. Ischemic heart disease edition 2.
9
Dermatopathy due to chemical substance. (60). Detailed explanation. 53. Contact dermatitis due to hair growth stimulant.
Interaction between drug and food. 60. II. Failure of treatment which occurs in the encounter of drug, food and favorite food. 3. Food attenuates the action of drug at the action site. b) Drug and coenzyme Q10.
Possibility and problem of bacteriophage therapy.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 1. Pharmacoepidemiology.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 2. Pharmacopedia and pharmacoepidemiology.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 3. Proper use of pharmaceutical products and pharmacoepidemiology.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 4. Medical information science and pharmacoepidemiology.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 5. Doctor and pharmacoepidemiology.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 6. Pharmacist and pharmacoepidemiology. Research on proper use of pharmaceutical products using the pharmacoepidemiological technique of the drug data accumulated in the hospital information system.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 7. Pharmacoepidemiology in public administration.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 8. Pharmacoepidemiology in the drug industry.
Future prospect of pharmacoepidemiology. To enroot proper use of pharmaceutical products. 9. For the development of pharmacoepidemiology. Through improvement of the clinical guideline on medical practice.
Pharmacy mixing business with the establishment of ambulatory chemotherapy center.
Actual conditions of medical examination to the hemicrania patient and present states of hemicrania diagnosis in primary care.
Clinical path and pharmacist. (19). Know how of plan and practice. Initial stage evaluation on admission and operation situation of NST path and analysis.
Prescription support by the pharmacist. 9. Prescription support for epilepsy treatment by the pharmacist.
QOL improvement in the patient and participation of the pharmacist. PART I. Hospital dispensing. (33). Present state of aseptic dispensing business in the intravenous hyperalimentation operation patient.
QOL improvement in the patient and participation of the pharmacist. PART II. Patient compliance instruction and ward activity. (45). Preparation of eating and swallowing approach manual. Information service for medical treatment staff.
Pharmacological basic knowledge required in the clinical field. (35). Aspects of laboratory test data. A case of an amyotrophic lateral sclerosis patient.
Sequel. Practical record of pharmacological management. (9). Essential sheet and follow-up sheet. Cardiovascular internal medicine domain - III. Cardiac insufficiency.
10
Dermatopathy due chemical substance.(61). Detailed explanation. 54. Ketoprofen: Photocontact dermatitis due to ketoprofen contained in Mohrus tape.
Problems of the medical care guideline of gastric ulcer.
Ppharmacopedia 6-year system and future prospect. Innovation of the medical education and the importance of clinical pharmacy education in the pharmaceutical sciences.
Significance and selected application of insulin preparation. 1. As the introduction. Innovation of insulin therapy.
Significance and selected application of insulin preparation. 2. Types and features of insulin preparation.
Significance and selected application of insulin preparation. 3. Points of insulin self-administration.
Significance and selected application of insulin preparation. 4. Infant and insulin therapy for type 1 diabetes mellitus.
Significance and selected application of insulin preparation. 5. Insulin therapy for type 2 diabetes mellitus.
Significance and selected application of insulin preparation. 5. Insulin therapy in the case associated with complication.
Significance and selected application of insulin preparation. 7. Psychology of the insulin self-administration patient and medical treatment guidance.
Significance and selected application of insulin preparation. 8. Summary. Future view of insulin therapy.
Preparation label and audit information system of the chemotherapeutic agent using Microsoft Access.
Combined effects of epinastine hydrochloride internal use in drug treatment with high-concentration active vitamin D3 for psoriasis vulgaris.
Risk management. Nosocomial activity of the pharmacist. (28). Risk management in the Kyushu Univ. hospital pharmacy.
Clinical pass and pharmacist. (20). Know-how of plan and practice. Trial of EBM introduction to cerebral infarction A pass (mild type cerebral infarction pass).
Prescription support by the pharmacist. 10. Role of the pharmacist in osteoporosis treatment. For continuous dosing of bisphosphonate preparation.
Interaction between drug and food. 61. III. Compatibility of drug and meal. 1. Acetaminophen and meal.
Pharmacological basic knowledge required in the clinical field. 36. Combined use of new quinolone antibacterial agent and non-steroidal anti-inflammatory analgesic. Risk of convulsion induction.
Sequel. Practical record of pharmacological management. (10). Essential sheet and follow-up sheet. Cardiovascular internal medicine domain. IV. Arrhythmia edition.
Xerosis and Sjoegren. 16. Mikulicz disease and Sjoegren syndrome.
Formidable sterility. 13. Motivation of sterility treatment. Considering in modesty together with patient.
11
Dermatopathy by the chemical substance.(62). Detailed explanation. 55. A case of contact dermatitis due to .EPSILON.-aminocaproic acid.
Selected application of inhalant. 1. General remarks: Significance and history of inhalant. Discrimination of chest physician according to whether he can use inhalant well.
Selected application of inhalant. 2. Inhalation therapy for adult. Especially inhalation for elderly person.
Selected application of inhalant. 3. Inhalation therapy in the pediatrics region.
Selected application of inhalant. 4. Types and features of the inhalant.
Selected application of inhalant. 5. Patient compliance instruction of inhalant.
Therapy with the antiviral drug and problems. 1. Influenza.
Therapy with the antiviral drug and problems. 2. Herpesvirus.
Therapy with the antiviral drug and problems. 3. Up-date antiviral drug for hepatitis.
Therapy with the antiviral drug and problems. 4. Human immunodeficiency virus (HIV).
Therapy with the antiviral drug and problems. 5. Viral infection and pharmaceutical care.
Therapy with the antiviral drug and problems. 6. Antiviral drug and patient compliance instruction. Centering on chronic hepatitis C.
Preparation of action mechanism map of anticancer drug. Antimetabolite series.
A case of epidermolysis bullosa dystrophica in which epinastine hydrochloride was useful for pruritus in the cicatrical part.
Action of raloxifene hydrochloride (Evista) on the lumbar: Usefulness of simultaneous combined use of alfacalcidol.
Clinical pass and pharmacist (21). Know-how of plan and practice. Examination to the drug proper use in the clinical pass.
Prescription support by the pharmacist. 11. Prescription support by the pharmacist utilizing the ordering system.
Interaction between drug and food. 62. III. Compatibility of drug and meal. 2. Nateglinide and meal.
Pharmacological basic knowledge required in the clinical field. 37. Drug management guidance business in the cardiovascular surgery ward. Valvular disease of heart and digitalis preparation.
Sequel. Practical record pharmacological management (11). Essential sheet and follow-up sheet. Systemic lupus erythematosus.
Xerosis and Sjoegren. 17. Improvement of saliva secretional capacity and QOL by cevimeline therapy for Sjoegren syndrome.
12
Dermatopathy by chemical substance.(63) Detailed explanation. 56. Chemical burn.(2)
Establishment of Pharmaceuticals and Medical Devices General Organization and expectation to new drug development.
Pharmacopedia of 6-year system and future prospect.
Practice of NST (nutrition support team). 1. Instead of introduction. Up-to-date significance of NST.
Practice of NST (nutrition support team). 2. Startup of NST and management system.
Practice of NST (nutrition support team). 3. Practical NST activity. 1) Nutrition assessment.
Practice of NST (nutrition support team). 3. Practical NST activity. 2) Selection of the nutritional administration method.
Practice of NST (nutrition support team). 3. Practical NST activity. 3) Round of visits and meeting.
Practice of NST (nutrition support team). 4. NST and team medical treatment cooperation.
Practice of NST (nutrition support team). 5. Effects of NST introduction.
Practice of NST (nutrition support team). 6. Strategy of NST activity continuation.
Evaluation of cefmetazole sodium injection on the basis of the difference in the color tone during the dissolution of the preparation.
Effect of suplatast tosylate on persistent coughing judged by the self-estimation according to the point.
Bitterness evaluation of azithromycin hydrate powder (Zithromac fine granule for children's use) by the taste sensor.
Risk management. Nosocomial activity of the pharmacist. (29). Risk management on the injection administration in the ward. Role of the resident pharmacist in surgery HCU.
Interaction between drug and food. 63. III. Compatibility of drug and meal. 3. Quazepam and meal.
Pharmacological basic knowledge required in the clinical field. 38. Cautionary supplement during operation and role of the pharmacist.
Sequel. Practical record of pharmacological management. (12). Essential sheet and follow-up sheet. Radiology region.
Xerosis and Sjoegren. 18. Fibromyalgia (fibrositis) and Sjoegren syndrome.